

Factor VII Deficiency (FVIIId)

IN YOUR WORLD, EXPERIENCE MATTERS



TAYLOR has FVIIId.



Is your FVIIId being treated?

FVIIId is a rare bleeding disorder in which there are low levels of factor VII in the blood. When there is not enough factor VII in the blood, clotting can take much longer than normal or may not occur at all. Males and females are equally affected.

FVIIId can be caused by an abnormal gene that is inherited from both parents. FVIIId can be detected at birth; however, some people with mild deficiency grow into adulthood without knowing they have it. FVIIId can also occur in people who are not born with it, due to a variety of causes.

Signs and symptoms of FVIIId

- Frequent nosebleeds
- Easy bruising
- Bleeding from the gums
- Heavy, prolonged menstrual bleeding in women
- Muscle and joint bleeds
- Intestinal bleeding
- Head bleeds in newborns
- Prolonged bleeding following surgery

FVIIId affects

1 in
500,000
people

Available treatments

- Fresh frozen plasma
- Recombinant activated factor VII concentrate

When left untreated, joint bleeds have the potential to cause permanent damage to your joints over time.

70% of patients with joint bleeds were less than 5 years of age, so early treatment with the right therapy is critical



NovoSeven® RT:

Experience where it matters

Controlling bleeds, whenever they happen

- Proven effective to treat FVII at home

Safety supported by clinical experience

- A low rate of blood clots has been reported in clinical trials

Speed when it's needed

- Fast to mix, fast to infuse, and fast to control bleeds^a

NovoSeven® RT—committed to your experience

- More than 30 years of research and long-term clinical experience^b

What is NovoSeven® RT?

NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:

- Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann's thrombasthenia with a decreased or absent response to platelet transfusions
- Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:

- **Serious blood clots** that form in veins and arteries with the use of NovoSeven® RT have been reported
- Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
- Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT

^aAdminister as a slow bolus injection over 2-5 minutes, depending on the dose administered.

^bCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.



TAYLOR has FVII deficiency.



Please see additional Important Safety Information throughout.
Please see accompanying Prescribing Information.


NovoSeven® RT
Coagulation Factor VIIa
(Recombinant)




Experience **proven bleed control** with NovoSeven® RT

Effectively stop bleeds

Surgical and nonsurgical bleeding episodes



Trial patients



Recombinant activated FVII (rFVIIa) is recommended by MASAC for FVIIId

MASAC=Medical and Scientific Advisory Council.

*From an analysis of published cases and people who took part in trials and registries.

NovoSeven® RT
Coagulation Factor VIIa
(Recombinant)



BARBARA has FVIIId.

Important Safety Information

What is the most important information I should know about NovoSeven® RT? (cont'd)

NovoSeven® RT may cause serious side effects, including: (cont'd)

- You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness



Please see additional Important Safety Information throughout.
Please see accompanying Prescribing Information.

NovoSeven® RT: **Established safety** profile that comes from experience^a

^aCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.

The safety of NovoSeven® RT is well studied

- Works at the site of injury
- **A low rate of blood clots** has been reported in clinical trials

Recombinant manufacturing minimizes the possibility of viral contamination

- Made without any human blood or plasma

Important Safety Information

What should I tell my healthcare provider before using NovoSeven® RT?

- Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:
 - congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
 - are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding
 - history of heart or blood vessel diseases
- Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies



TAYLOR has FVIIId.



Please see additional Important Safety Information throughout.
Please see accompanying Prescribing Information.

NovoSeven® RT
Coagulation Factor VIIa
(Recombinant)





BARBARA has FVIIId.

Experience **fast mixing and infusing** with NovoSeven® RT

NovoSeven® RT with MixPro® is fast to mix

- Prefilled syringe means no extra steps to fill a syringe with diluent

Fast to infuse

- NovoSeven® RT is given as an intravenous (IV) bolus injection
- NovoSeven® RT provides low infusion volume*
- Infusing NovoSeven® RT takes only 2 to 5 minutes



NovoSeven® RT
90 mcg/kg
2-5
minutes

Important Safety Information

What are the possible side effects of NovoSeven® RT?

- The most common and serious side effects are blood clots
- Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction

Visit **NovoSevenRT.com** to find a local Novo Nordisk Representative and request a Patient Starter Kit

*Administer as a slow bolus injection over 2 to 5 minutes, depending on the dose administered.



NovoSeven® RT: Experience where it matters



Controlling bleeds, whenever they happen

- Proven effective to treat FVII deficiency at home

Safety supported by clinical experience

- A low rate of blood clots has been reported in clinical trials

Speed when it's needed

- Fast to mix, fast to infuse, and fast to control bleeds^a

NovoSeven® RT—committed to your experience

- More than 30 years of research and long-term clinical experience^b



Learn more at NovoSevenRT.com

^aAdminister as a slow bolus injection over 2-5 minutes, depending on the dose administered.

^bCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.

XAVIER has FVIIId.

Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:

- **Serious blood clots** that form in veins and arteries with the use of NovoSeven® RT have been reported
- Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
- Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT

Please see additional Important Safety Information throughout.

Please see accompanying Prescribing Information.

Novo Nordisk Inc., 800 Scudders Mill Road,
Plainsboro, New Jersey 08536 U.S.A.

MixPro® and NovoSeven® are registered trademarks
of Novo Nordisk Health Care AG.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

© 2019 Novo Nordisk Printed in the U.S.A.

US19NSVN00008 January 2019



NovoSeven® RT
Coagulation Factor VIIa
(Recombinant)

